Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019.

ABSTRACT:

Background aims

The acute respiratory distress syndrome (ARDS) resulting from coronavirus disease 2019 (COVID-19) is associated with a massive release of inflammatory cytokines and high mortality. Mesenchymal stromal cells (MSCs) have anti-inflammatory properties and have shown activity in treating acute lung injury. Here the authors report a case series of 11 patients with COVID-19-associated ARDS (CARDS) requiring mechanical ventilation who were treated with remestemcel-L, an allogeneic MSC product, under individual patient emergency investigational new drug applications.

Methods

Patients were eligible if they were mechanically ventilated for less than 72 h prior to the first infusion. Patients with pre-existing lung disease requiring supplemental oxygen or severe liver or

SUBMITTER: Whittaker Brown SA 

PROVIDER: S-EPMC8995321 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature